-
公开(公告)号：US10584160B2
公开(公告)日：2020-03-10
申请号：US15760449
申请日：2016-09-22
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Dasa Lipovsek , Joseph Toth , Ginger C. Rakestraw , Irvith M. Carvajal , Stanley Richard Krystek, Jr. , Steven R. O'Neil , Guodong Chen , Richard Y. Huang , Bryan C. Barnhart , John Thomas Loffredo , Christina Terragni
Abstract: Provided herein are polypeptides which include tenth fibronectin type III domains (10Fn3) that bind to glypican-3. Also provided are fusion molecules comprising a 10Fn3 domain that bind to glypican-3 for use in diagnostic and therapeutic applications. Glypican-3 10Fn3 drug conjugates are also provided.
-
公开(公告)号：US20220204618A1
公开(公告)日：2022-06-30
申请号：US17670398
申请日：2022-02-11
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Natalie Bezman , Alan J. Korman , Shrikant Deshpande , Amy D. Jhatakia , Richard Y. Huang , Guodong Chen , Ginger C. Rakestraw , Karla Ann Henning , Vangipuram S. Rangan , Christine Bee , Xiang Shao
IPC: C07K16/28 , A61K39/395 , A61P35/00
Abstract: The present disclosure provides isolated monoclonal antibodies (e.g., humanized and human monoclonal antibodies), or antigen-binding fragments thereof, that specifically bind to human natural killer cell inhibitory receptor group 2A (NKG2A) protein with high affinity and exhibit therapeutically desirable functional properties, such as for the treatment of, for example, cancer. Immunoconjugates, bispecific molecules, and pharmaceutical compositions comprising the anti-NKG2A antibodies of the invention are also provided. Nucleic acid molecules encoding the antibodies, expression vectors, host cells, and methods of treatment of, for example, cancer using the antibodies are further provided. Combination therapy, in which an anti-NKG2A antibody in the present disclosure is co-administered with at least one additional agent such as another antibody (e.g., anti-PD-1, anti-PD-L1, and/or anti-CTLA-4 antibodies), is also provided.
-
公开(公告)号：US20210395392A1
公开(公告)日：2021-12-23
申请号：US17284119
申请日：2019-10-08
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Thomas E. Spires, Jr. , Michael Quigley , Virginie Lafont , Ginger C. Rakestraw , Linda Liang , Karen A. Augustine-Rauch
Abstract: This disclosure provides isolated antibodies that bind specifically to MerTK expressed on the surface of a cell and inhibit efferocytosis by the MerTK-expressing cell. The disclosure provides methods for treating a subject afflicted with a cancer comprising administering to the subject a therapeutically effective amount of an anti-MerTK antibody as monotherapy or in combination with a checkpoint inhibitor, such as an anti-PD-1 or anti-PD-L1 antibody.
-
公开(公告)号：US20180201665A1
公开(公告)日：2018-07-19
申请号：US15819925
申请日：2017-11-21
Applicant: Bristol-Myers Squibb Company
Inventor： Ray Camphausen , Jonathan H. Davis , Sharon T. Cload , Fabienne M. Denhez , Amna Saeed-Kothe , Dasa Lipovsek , Ching-Hsiung Frederick Lo , Chee Meng Low , Bowman Miao , Tracy S. Mitchell , Rex A. Parker , Ginger C. Rakestraw , Katie A. Russo , Doree F. Sitkoff
Abstract: The present invention relates to fibronectin based scaffold domain proteins that bind PCSK9. The invention also relates to the use of the innovative proteins in therapeutic applications to treat atherosclerosis, hypercholesterolemia and other cholesterol related diseases. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative protein.
-
公开(公告)号：US12077584B2
公开(公告)日：2024-09-03
申请号：US17670398
申请日：2022-02-11
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Natalie Bezman , Alan J. Korman , Shrikant Deshpande , Amy D. Jhatakia , Richard Y. Huang , Guodong Chen , Ginger C. Rakestraw , Karla Ann Henning , Vangipuram S. Rangan , Christine Bee , Xiang Shao
IPC: C07K16/28 , A61K39/00 , A61K39/395 , A61K47/68 , A61P35/00 , C07K1/22 , C12N5/071 , C12N15/85 , C12P21/00 , G01N33/68
CPC classification number: C07K16/2803 , A61K39/3955 , A61K47/6849 , A61P35/00 , C07K1/22 , C12N5/0682 , C12N15/85 , C12P21/005 , G01N33/68 , A61K2039/505 , A61K2039/507 , C07K2317/21 , C07K2317/24 , C07K2317/31 , C07K2317/33 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/77 , C07K2317/92 , C07K2317/94 , C12N2510/02 , C12N2800/107
Abstract: The present disclosure provides isolated monoclonal antibodies (e.g., humanized and human monoclonal antibodies), or antigen-binding fragments thereof, that specifically bind to human natural killer cell inhibitory receptor group 2A (NKG2A) protein with high affinity and exhibit therapeutically desirable functional properties, such as for the treatment of, for example, cancer. Immunoconjugates, bispecific molecules, and pharmaceutical compositions comprising the anti-NKG2A antibodies of the invention are also provided. Nucleic acid molecules encoding the antibodies, expression vectors, host cells, and methods of treatment of, for example, cancer using the antibodies are further provided. Combination therapy, in which an anti-NKG2A antibody in the present disclosure is co-administered with at least one additional agent such as another antibody (e.g., anti-PD-1, anti-PD-L1, and/or anti-CTLA-4 antibodies), is also provided.
-
Patent Agency Ranking
公开(公告)号：US20160159883A1
公开(公告)日：2016-06-09
申请号：US14956698
申请日：2015-12-02
Applicant: Bristol-Myers Squibb Company
Inventor： Ray Camphausen , Jonathan H. Davis , Sharon T. Cload , Fabienne M. Denhez , Amna Saeed-Kothe , Dasa Lipovsek , Ching-Hsiung Frederick Lo , Chee Meng Low , Bowman Miao , Tracy S. Mitchell , Rex A. Parker , Ginger C. Rakestraw , Katie A. Russo , Doree F. Sitkoff
CPC classification number: C07K14/78 , A61K38/39 , A61K47/549 , A61K47/60 , C07K16/18 , C07K16/40 , C07K2318/20 , C07K2319/30 , C07K2319/31 , C07K2319/70 , C12N9/6424
Abstract: The present invention relates to fibronectin based scaffold domain proteins that bind PCSK9. The invention also relates to the use of the innovative proteins in therapeutic applications to treat atherosclerosis, hypercholesterolemia and other cholesterol related diseases. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative protein.
-
公开(公告)号：US11981734B2
公开(公告)日：2024-05-14
申请号：US17668807
申请日：2022-02-10
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Natalie Bezman , Alan J. Korman , Shrikant Deshpande , Amy D. Jhatakia , Richard Y. Huang , Guodong Chen , Ginger C. Rakestraw , Karla Ann Henning , Vangipuram S. Rangan , Christine Bee , Xiang Shao
IPC: C07K16/28 , A61K39/395 , A61K47/68 , A61P35/00 , C07K1/22 , C12N5/071 , C12N15/85 , C12P21/00 , G01N33/68 , A61K39/00
CPC classification number: C07K16/2803 , A61K39/3955 , A61K47/6849 , A61P35/00 , C07K1/22 , C12N5/0682 , C12N15/85 , C12P21/005 , G01N33/68 , A61K2039/505 , A61K2039/507 , C07K2317/21 , C07K2317/24 , C07K2317/31 , C07K2317/33 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/77 , C07K2317/92 , C07K2317/94 , C12N2510/02 , C12N2800/107
Abstract: The present disclosure provides isolated monoclonal antibodies (e.g., humanized and human monoclonal antibodies), or antigen-binding fragments thereof, that specifically bind to human natural killer cell inhibitory receptor group 2A (NKG2A) protein with high affinity and exhibit therapeutically desirable functional properties, such as for the treatment of, for example, cancer. Immunoconjugates, bispecific molecules, and pharmaceutical compositions comprising the anti-NKG2A antibodies of the invention are also provided. Nucleic acid molecules encoding the antibodies, expression vectors, host cells, and methods of treatment of, for example, cancer using the antibodies are further provided. Combination therapy, in which an anti-NKG2A antibody in the present disclosure is co-administered with at least one additional agent such as another antibody (e.g., anti-PD-1, anti-PD-L1, and/or anti-CTLA-4 antibodies), is also provided.
-
公开(公告)号：US10947297B2
公开(公告)日：2021-03-16
申请号：US15819925
申请日：2017-11-21
Applicant: Bristol-Myers Squibb Company
Inventor： Ray Camphausen , Jonathan H. Davis , Sharon T. Cload , Fabienne M. Denhez , Amna Saeed-Kothe , Dasa Lipovsek , Ching-Hsiung Frederick Lo , Chee Meng Low , Bowman Miao , Tracy S. Mitchell , Rex A. Parker , Ginger C. Rakestraw , Katie A. Russo , Doree F. Sitkoff
IPC: A61K39/00 , A61K39/44 , C07K4/00 , C07K14/00 , C07K14/78 , A61K38/39 , C12N9/64 , A61K47/60 , A61K47/54 , C07K16/18 , C07K16/40
Abstract: The present invention relates to fibronectin based scaffold domain proteins that bind PCSK9. The invention also relates to the use of the innovative proteins in therapeutic applications to treat atherosclerosis, hypercholesterolemia and other cholesterol related diseases. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative protein.
-
公开(公告)号：US09856309B2
公开(公告)日：2018-01-02
申请号：US14956698
申请日：2015-12-02
Applicant: Bristol-Myers Squibb Company
Inventor： Ray Camphausen , Jonathan H. Davis , Sharon T. Cload , Fabienne M. Denhez , Amna Saeed-Kothe , Dasa Lipovsek , Ching-Hsiung Frederick Lo , Chee Meng Low , Bowman Miao , Tracy S. Mitchell , Rex A. Parker , Ginger C. Rakestraw , Katie A. Russo , Doree F. Sitkoff
CPC classification number: C07K14/78 , A61K38/39 , A61K47/549 , A61K47/60 , C07K16/18 , C07K16/40 , C07K2318/20 , C07K2319/30 , C07K2319/31 , C07K2319/70 , C12N9/6424
Abstract: The present invention relates to fibronectin based scaffold domain proteins that bind PCSK9. The invention also relates to the use of the innovative proteins in therapeutic applications to treat atherosclerosis, hypercholesterolemia and other cholesterol related diseases. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative protein.
-
公开(公告)号：US09234027B2
公开(公告)日：2016-01-12
申请号：US13835639
申请日：2013-03-15
Applicant: Bristol-Myers Squibb Company
Inventor： Ray Camphausen , Jonathan H. Davis , Sharon T. Cload , Fabienne M. Denhez , Amna Saeed-Kothe , Dasa Lipovsek , Ching-Hsiung Frederick Lo , Chee Meng Low , Bowman Miao , Tracy S. Mitchell , Rex A. Parker , Ginger C. Rakestraw , Katie A. Russo , Doree F. Sitkoff
CPC classification number: C07K14/78 , A61K38/39 , A61K47/549 , A61K47/60 , C07K16/18 , C07K16/40 , C07K2318/20 , C07K2319/30 , C07K2319/31 , C07K2319/70 , C12N9/6424
Abstract: The present invention relates to fibronectin based scaffold domain proteins that bind PCSK9. The invention also relates to the use of the innovative proteins in therapeutic applications to treat atherosclerosis, hypercholesterolemia and other cholesterol related diseases. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative protein.
Abstract translation: 本发明涉及结合PCSK9的基于纤连蛋白的支架结构域蛋白。 本发明还涉及创新的蛋白质在治疗应用中用于治疗动脉粥样硬化，高胆固醇血症和其它胆固醇相关疾病的用途。 本发明还涉及包含这种蛋白质的细胞，编码这种蛋白质或其片段的多核苷酸，以及包含编码该创新蛋白质的多核苷酸的载体。
-
-
-
-
-
-
-
-
-
Search Results
14
records
(took 0.021 seconds)
